[Prevention of peritoneal recurrence by combined intra-peritoneal and intra-tumoral injections of OK-432].
Protective effect of OK-432 on peritoneal recurrence was examined in an experimental mouse model with Meth A fibrosarcoma injected into both abdominal wall and intraperitoneal cavity. OK-432 was given through either intratumoral (i.t.), intradermal (i.d.), intraperitoneal (i.p.), or i.p. + i.t. route. A significant antitumor effect against abdominal tumor was observed in mice given i.t. or i.p. + i.t. injection of OK-432. A significant protective effect against peritoneal recurrence and prolonged survival time was obtained in an i.p. + i.t. group, although other treatment groups showed only minimal effect. We conclude that combined i.p. and i.t. administration of OK-432 may prevent peritoneal recurrence and lead to prolongation in clinical patients with advanced GI tract cancer.
Baba
H
H
Dept. of Surgery II, Faculty of Medicine, Kyushu University.
Tsujitani
S
S
Korenaga
D
D
Kakeji
Y
Y
Haraguchi
M
M
Konoe
S
S
Maehara
Y
Y
Sugimachi
K
K
D000818:Animals; D001688:Biological Products / Q000008:administration & dosage*; D005260:Female; D005354:Fibrosarcoma / Q000473:pathology / Q000628:therapy*; D015552:Injections, Intralesional; D007274:Injections, Intraperitoneal; D051379:Mice; D008807:Mice, Inbred BALB C; D010534:Peritoneal Neoplasms / Q000517:prevention & control* / Q000556:secondary; D010844:Picibanil / Q000008:administration & dosage* / Q000627:therapeutic use; D011379:Prognosis; D012513:Sarcoma, Experimental / Q000473:pathology / Q000628:therapy
D001688:Biological Products; D010844:Picibanil